Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Category: #health  | By Mateen Dalal  | Date: 2019-12-04 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Applications) for generic editions of Amicar® (aminocaproic acid) Tablets USP, 500 mg and Revatio® for Oral Suspension 10 mg/ml.

According to a statement, Chintu Patel, Co-CEO, Amneal, said that their company is delighted to introduce these new drugs to healthcare providers and patients. He claims that their firm’s diverse and large pipeline has managed to deliver 36 new generic items in 2019 across multiple dosage forms.

Reportedly, Amneal had earlier bagged the designation of Competitive Generic Therapy (CGT) from the FDA for the generic version of Amicar®. Considering its first approved application, the biotech has been offered 180 days of CGT exclusivity.

Prior to this news, Amneal was in limelight for the launch of the generic version of Invega® (paliperidone). The drug was introduced in extended-release tablets ranging from 1.5mg to 9mg.

Speaking of which, Patel said that the company is pleased to get an approval for the launch of the generic version of Invega. It marks as one of 15 complex drugs that the firm expects to launch over 24-month.

Moreover, with a varied lineup of over 170 products, the company hopes to progress these types of complex product approvals, which would further expand its portfolio. Also, such moves would allow patients to buy generic medicines at affordable prices, cites Patel.

For the record, Amneal Pharmaceuticals, Inc. is based in Bridgewater, New Jersey. It is an integrated pharmaceutical firm focused on manufacturing, developing and distributing branded, generic, and biosimilar products. Amneal has operations in Asia, North America and Europe, and is working on bringing high-quality medicines to patients primarily within the U.S.
 

Source Credit: https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-Announces-the-Approval-and-Launch-of-Generic-Revatio-for-Oral-Suspension-and-Generic-Amicar-Tablets/default.aspx

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

UK’s Health Secretary announces 10-year plan to tackle dementia

UK’s Health Secretary announces 10-year plan to tackle dementia

By Mateen Dalal

The UK Health and Social Care Secretary, Sajid Javid, has reportedly announced a novel 10-year plan to effectively tackle dementia and to increase funding in research to get a better understanding of neurodegenerative diseases. As per sources, at ...

Starbucks to cover abortion related travel expenses for workers

Starbucks to cover abortion related travel expenses for workers

By Mateen Dalal

Starbucks has reportedly announced that it would start covering all eligible travel expenditures for the workers seeking gender-affirming surgical procedures or abortions. As per reports, the coffee conglomerate has joined Apple, Amazon, Salesforc...

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

By Mateen Dalal

The on-going conflict between Russia and Ukraine has adversely affected the fish and chips industry in the United Kingdom, driving the closure of centuries-old shops, sharp price hikes, and change in menus. The National Federation of Fish Friers (...